Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, Fulkerson J, Zak DE, Walker R, McClain B, Sadoff J, Scott J, Shepherd B, Ishmukhamedov J, Hokey DA, Dheenadhayalan V, Shankar S, Amon L, Navarro G, Podyminogin R, Aderem A, Barker L, Brennan M, Wallis RS, Gershon AA, Gershon MD, Steinberg S.

EBioMedicine. 2016 May;7:278-86. doi: 10.1016/j.ebiom.2016.04.010. Epub 2016 Apr 19.

2.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 May 6;7:11633. doi: 10.1038/ncomms11633. No abstract available.

3.

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.

4.

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

Sheehan S, Harris SA, Satti I, Hokey DA, Dheenadhayalan V, Stockdale L, Manjaly Thomas ZR, Minhinnick A, Wilkie M, Vermaak S, Meyer J, O'Shea MK, Pau MG, Versteege I, Douoguih M, Hendriks J, Sadoff J, Landry B, Moss P, McShane H.

PLoS One. 2015 Nov 3;10(11):e0141687. doi: 10.1371/journal.pone.0141687. eCollection 2015.

5.

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070. Epub 2015 Apr 28.

PMID:
25936724
6.

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).

Churchyard GJ, Snowden MA, Hokey D, Dheenadhayalan V, McClain JB, Douoguih M, Pau MG, Sadoff J, Landry B.

Vaccine. 2015 Apr 8;33(15):1890-6. doi: 10.1016/j.vaccine.2015.02.004. Epub 2015 Feb 17.

PMID:
25698492
7.

A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Hokey DA, Wachholder R, Darrah PA, Bolton DL, Barouch DH, Hill K, Dheenadhayalan V, Schwander S, Godin CS, Douoguih M, Pau MG, Seder RA, Roederer M, Sadoff JC, Sizemore D.

Hum Vaccin Immunother. 2014;10(8):2199-210. doi: 10.4161/hv.29108.

8.

Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402).

Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J.

Vaccine. 2010 Jun 17;28(27):4369-75. doi: 10.1016/j.vaccine.2010.04.059. Epub 2010 May 2.

PMID:
20444437
9.

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.

Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, Cantarero L, Basaraba RJ, Bang P, Kromann I, McMclain JB, Sadoff JC, Andersen P.

Vaccine. 2010 Jan 22;28(4):1084-93. doi: 10.1016/j.vaccine.2009.10.114. Epub 2009 Nov 5.

PMID:
19896449
10.

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC.

Vaccine. 2009 Jul 16;27(33):4412-23. doi: 10.1016/j.vaccine.2009.05.048. Epub 2009 Jun 2.

PMID:
19500523
11.

The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis.

Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL.

Vaccine. 2008 Nov 11;26(48):6092-8. doi: 10.1016/j.vaccine.2008.09.011. Epub 2008 Sep 20.

PMID:
18809446
12.

Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice.

Jeon BY, Derrick SC, Lim J, Kolibab K, Dheenadhayalan V, Yang AL, Kreiswirth B, Morris SL.

Infect Immun. 2008 Nov;76(11):5173-80. doi: 10.1128/IAI.00019-08. Epub 2008 Aug 18.

13.
14.

A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen.

Parra M, Cadieux N, Pickett T, Dheenadhayalan V, Brennan MJ.

Infect Immun. 2006 Jan;74(1):786-9.

15.

Expression of the PE_PGRS 33 protein in Mycobacterium smegmatis triggers necrosis in macrophages and enhanced mycobacterial survival.

Dheenadhayalan V, Delogu G, Brennan MJ.

Microbes Infect. 2006 Jan;8(1):262-72. Epub 2005 Sep 12.

PMID:
16203168
16.

The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis.

Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, Locht C, Brennan MJ.

Infect Immun. 2004 Dec;72(12):6799-805.

17.
18.

Cloning and characterization of the genes coding for antigen 85A, 85B and 85C of Mycobacterium avium subsp. paratuberculosis.

Dheenadhayalan V, Shin KS, Chang CF, Chang CD, Wang SJ, McDonough S, McDonough P, Stehman S, Shin S, Torres A, Chang YF.

DNA Seq. 2002 Oct;13(5):287-94.

PMID:
12592709
19.

Association of interleukin-10 cytokine expression status with HLA non-DRB1*02 and Mycobacterium bovis BCG scar-negative status in south Indian pulmonary tuberculosis patients.

Dheenadhayalan V, Shanmugalakshmi S, Vani S, Muthuveeralakshmi P, Arivarignan G, Nageswari AD, Pitchappan RM.

Infect Immun. 2001 Sep;69(9):5635-42.

20.

Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India.

Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN, Balakrishnan K, Pitchappan RM.

Tuber Lung Dis. 1999;79(5):309-17.

PMID:
10707259

Supplemental Content

Loading ...
Support Center